Quick Answer
CytoDyn Inc. reported Research And Development Expense of $7.24 million for the year ending 2024.
- CytoDyn Inc. showed an increase of +175.1% in Research And Development Expense from 2023 to 2024.
- This data is from CytoDyn Inc.'s annual report (Form 10-K), filed with the SEC on August 15, 2024.
- XBRL data for this metric is available from 2011 to 2024 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: $71.5 thousand | Q3 2012: $60.5 thousand | Q4 2012: $161.0 thousand | Q1 2013: $33.4 thousand | Q3 2013: $158.6 thousand | Q4 2013: $542.8 thousand | Q1 2014: $1.66 million | Q3 2014: $2.06 million | Q4 2014: $2.09 million | Q1 2015: $2.26 million | Q3 2015: $5.31 million | Q4 2015: $1.66 million | Q1 2016: $2.74 million | Q3 2016: $3.69 million | Q4 2016: $4.38 million | Q1 2017: $6.53 million | Q3 2017: $8.15 million | Q4 2017: $9.08 million | Q1 2018: $12.08 million | Q3 2018: $11.40 million | Q4 2018: $12.87 million | Q1 2019: $9.02 million | Q3 2019: $9.06 million | Q4 2019: $8.53 million | Q1 2020: $15.11 million | Q3 2020: $15.19 million | Q4 2020: $16.45 million | Q1 2021: $12.32 million | Q3 2021: $12.02 million | Q4 2021: $7.45 million | Q1 2022: $3.57 million | Q3 2022: $576.0 thousand | Q4 2022: $137.0 thousand | Q1 2023: $938.0 thousand | Q3 2023: $1.91 million | Q4 2023: $1.08 million | Q1 2024: $650.0 thousand.
- Over the full 14 years of available data (2011 to 2024), CytoDyn Inc.'s Research And Development Expense has grown by 1,405.9%.
- Historical annual values: Fiscal year 2024: $7.24 million | Fiscal year 2023: $2.63 million | Fiscal year 2022: $27.04 million | Fiscal year 2021: $53.40 million | Fiscal year 2020: $52.64 million | Fiscal year 2019: $42.49 million | Fiscal year 2018: $38.22 million | Fiscal year 2017: $20.21 million | Fiscal year 2016: $13.73 million | Fiscal year 2015: $15.16 million | Fiscal year 2014: $3.98 million | Fiscal year 2013: $619.8 thousand | Fiscal year 2012: $530.0 thousand | Fiscal year 2011: $480.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: